Latest Comments

EULAR 2017: Big pharma dives back into the lupus pipeline

EULAR 2017: Big pharma dives back into the lupus pipeline

GSK’s tafenoquine could spell the end for relapsing P. vivax malaria

GSK’s tafenoquine could spell the end for relapsing P. vivax malaria

EULAR 2017: Mixed Expectations on Use of Biosimilars in Rheumatoid Arthritis

EULAR 2017: Mixed Expectations on Use of Biosimilars in Rheumatoid Arthritis

U-turn: life-prolonging breast cancer drug now available on the NHS

U-turn: life-prolonging breast cancer drug now available on the NHS

Understanding the risk of over treatment in Type 2 Diabetes

Understanding the risk of over treatment in Type 2 Diabetes

Loss of exclusivity to limit J&J gain after Zytiga label extension

Loss of exclusivity to limit J&J gain after Zytiga label extension

Chemo-free triplet regimens on the horizon for CLL

Chemo-free triplet regimens on the horizon for CLL

Poor tolerability of Opdivo + Yervoy in frontline NSCLC could be Achilles heel

Poor tolerability of Opdivo + Yervoy in frontline NSCLC could be Achilles heel

Increased risk of amputation if taking type 2 diabetes drug Invokana

Increased risk of amputation if taking type 2 diabetes drug Invokana

Highlights from the 2017 ATS Conference: positive results for AstraZeneca’s Daliresp beyond reducing the risk of exacerbations

Highlights from the 2017 ATS Conference: positive results for AstraZeneca’s Daliresp beyond reducing the risk of exacerbations

Pacific Biosciences: don’t count them out yet

Pacific Biosciences: don’t count them out yet

Gilead and AbbVie look to fill remaining gaps in Hepatitis C treatment

Gilead and AbbVie look to fill remaining gaps in Hepatitis C treatment

Novartis boosts ophthalmology pipeline by in-licensing clinical-stage dry eye therapy

Novartis boosts ophthalmology pipeline by in-licensing clinical-stage dry eye therapy

FDA’s acceptance of Santen’s Opsiria marks a milestone for the company

FDA’s acceptance of Santen’s Opsiria marks a milestone for the company

The likely relocation of the EMA is bad news for the pharmaceutical industry and the health of 500 million Europeans

The likely relocation of the EMA is bad news for the pharmaceutical industry and the health of 500 million Europeans

Researchers raise hope for affordable malaria diagnostics

Researchers raise hope for affordable malaria diagnostics

Agios’s enasidenib is on track to become the first IDH2 inhibitor approved in AML

Agios’s enasidenib is on track to become the first IDH2 inhibitor approved in AML

WHO’s first global hepatitis report aims high: elimination of hepatitis B and C by 2030

WHO’s first global hepatitis report aims high: elimination of hepatitis B and C by 2030

China’s pharma market transformation to fuel global industry growth

China’s pharma market transformation to fuel global industry growth

Mundipharma to market Invossa in Korea, marking another strategic partnership for Kolon Life Science

Mundipharma to market Invossa in Korea, marking another strategic partnership for Kolon Life Science

Pharma price hiking: why does it happen?

Pharma price hiking: why does it happen?